MCL1 and cancer: Treatment of colorectal cancer cells and mesothelioma cells with HSP90 inhibitors resulted in rapid degradation of MCL-1 protein specifically in the cancer cells, causing a sensitisation to TRAIL (Lee et al, 2015) and ABT-737 (Busacca et al, 2015), respectively.